Phosphogliv forte, capsules 50 pcs

Pharmacotherapeutic group: hepatoprotective agent

ATX code: [A05VA]

Pharmacological properties.

Combined remedy. It has membrane stabilizing, hepatoprotective and antiviral effects.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cell and intracellular membranes and can restore their structure and functions in case of damage, having cytoprotective effect.

Normalizes protein and lipid metabolism, prevents loss of enzymes and other active substances by hepatocytes, restores detoxication function of the liver and inhibits formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.

Glycyrate (glycyrrhizic acid and salts) has anti-inflammatory effects, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increasing the activity of natural killer cells. It has hepatoprotective effect due to antioxidant and membrane stabilizing activity. Potentiates the effect of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effect in non-infectious liver lesions.

In skin lesions due to the membrane stabilizing and anti-inflammatory action of the components limits the spread of the process and promotes the regression of the disease.

Pharmacokinetics.

Phosphatidylcholine

Over 90% of phospholipids ingested are absorbed in the small intestine. Most of them are broken down by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with lymph stream enters blood, from where it is mainly bound with high density lipoproteins to liver. Pharmacokinetics in humans have been studied with the radioactively labeled ³H (choline portion) and ¹⁴C (linoleic acid residue) dilenoleoylphosphatidylcholine. Maximum concentration of ³H is reached after 6-24 hours, constituting 19.9% of the prescribed dose; ¹⁴C is reached after 4-12 hours, constituting 27.9%. The elimination half-life of the choline component is 66 hours and that of the linoleic acid residue 32 hours. In the feces, 2% ³H and 4.5% ¹⁴C are detected; in the urine, 6% ³H and a minimal amount ¹⁴C. Both isotopes are more than 90% absorbed in the gut.

Glycyrrhizic acid

. After oral administration in the intestine under the influence of the enzyme β-glucuronidase produced by bacteria of normal microflora, from glycyrrhizic acid is formed the active metabolite – β-glycyrrhetic acid, which is absorbed into the systemic bloodstream. In the blood β-glycyrrhetic acid binds with albumin and is almost completely transported to the liver. Excretion of β-glycyrrhetic acid occurs mainly in bile, with residual amount in urine.

According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and rate of its absorption by more than 2-fold.

Indications

Hepatitis, After a course of antibiotic therapy, Neurodermatitis, Nausea, Eczema, Jaundice, Alcoholism, Poisoning, Psoriasis, Weakness and fatigue, Liver damage

Fatty liver dystrophy (fatty hepatosis), alcoholic, toxic, including drugs, liver damage;

In the complex treatment of viral hepatitis, cirrhosis of the liver, psoriasis.

Active ingredient

Glycyrrhizic acid, Phospholipids

Composition

Active ingredients: Phospholipids (Lipoid PPL-400) – 400.0 mg [in terms of 100% substance (major component – phosphatidylcholine 73 to 79%) – 300.0 mg;

Glycyrrhizinate sodium (trisodium salt of glycyrrhizic acid) – 65.0 mg.

Excipients: butylhydroxytoluene – 0.1 mg, ethanol (ethyl alcohol) 95% – 12.0 mg, sunflower oil – 22.9 mg;

Solid gelatin capsules № 0 -96.0 mg.

[Capsule composition:

Case and cap: titanium dioxide (E 171) – 0.3333 %, iron oxide red dye (E 172) – 0.9300 %, iron oxide yellow dye (E 172) – 0.2000 %, iron oxide black dye (E 172) – 0.5300 %, gelatin – to 100.0 %]

How to take, the dosage

Taken orally, with meals, drinking small amounts of water. Adults take 1-2 capsules 3 times a day, children over 12 years – 1 capsule 3 times a day. The duration of therapy is determined by the doctor.

Interaction

Glycyrrhizic acid is a synergist of corticosteroid hormones, increases and prolongs their action.

Special Instructions

Impact on the ability to drive vehicles and mechanisms

The use of the drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Synopsis

Solid gelatin capsules № 0; the body and the cap of the capsule are brown.

The contents of capsules – oily paste-like mass of light yellow to orange-brown color with a slight specific smell.

Contraindications

Antiphospholipid syndrome; hypersensitivity to the components of the drug; pregnancy, breast-feeding, children under 12 years of age.

Side effects

Allergic reactions:skin rash, difficulty of nasal breathing, conjunctivitis, cough.

Cardiovascular system disorders:transient (transient) increase in blood pressure, peripheral edema.

Digestive system disorders:dyspeptic phenomena (belching, nausea, abdominal bloating), feeling of discomfort in the stomach.

In case of the above symptoms, discontinue the drug and consult a physician.

Overdose

Symptoms of overdose: storage of sodium and fluid in the body, manifested by peripheral edema and increased blood pressure; hyponatremia.

Treatment: depending on the severity of symptoms of overdose, it is necessary to reduce the dose of the drug and/or prescribe spironolactone 50-100 mg per day.

Pregnancy use

The drug is contraindicated in pregnancy and during breastfeeding (data on efficacy and safety are insufficient).

Similarities

Fosfogliv